Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma (KS)-associated herpesvirus, is the cause of KS. Human immunodeficiency virus (HIV) type 1 infection is a potent cofactor for the aggressive AIDS-related variant of this vascular tumor [1, 2] . In Western countries, KS is more common among HIV-1-infected homosexual men than among HIV-1-infected heterosexuals, drug users, transfusion recipients, or persons with hemophilia [3] . On the basis of this risk distribution, HHV-8 transmission is predicted to be predominantly sexual, with rare transmission through blood [3] . Several studies demonstrated sexual transmission of HHV-8 among homosexual men, who have high HHV-8 prevalence and incidence [4] [5] [6] [7] . Risk factor studies for HHV-8 in other HIV-1 transmission groups are scarce [8, 9] .
To elucidate modes of HHV-8 transmission among drug users in Amsterdam, we investigated the association between HHV-8 seropositivity and potential risk factors, including injection drug use (IDU). This study was conducted among a large prospective cohort of drug users, using a screening-confirmation protocol to detect HHV-8 antibodies [10] .
Methods
Study population. Between December 1985 and December 1996, 1218 injection and noninjection drug users were recruited into a prospective cohort study of HIV-1 infection and AIDS in Amsterdam. Most subjects were recruited at low-threshold methadone programs and sexually transmitted disease clinics for drug-using prostitutes. Participation was voluntary, regardless of HIV-1 status. Follow-up visits were scheduled every 4 months. At that time, a medical history was taken, blood samples were obtained, and a standardized behavioral questionnaire was administered by trained nurses [11] . Banked serum samples, stored at 2 70 C, were unavailable for 39 (3.2%) participants because of paucity of clinical material. We used data from the remaining 1179 participants in the present study.
Serologic assays and study definitions. The most recently obtained serum sample for each participant was tested with an EIA system based on HHV-8 lytic capsid (open-reading frame [ORF] 65) and latent nuclear (ORF73) antigens. Subsequent testing of baseline and intervening samples from seropositive participants differentiated persistently seropositive subjects from seroconverters; these results have been published elsewhere [5] . The specificity of the combined EIA format (positive for ORF65, ORF73, or both) is 90.7% (95% confidence interval [CI], 86.9%-93.8%) [4] . Serum samples that were found to have antibodies to HHV-8 ORF65 or ORF73 in the EIA system were confirmed by well-described and more specific assays: Western blot and a recombinant ORF65 protein and an IFA for the latent nuclear antigen [10] . No seroreversion events were noted after confirmed seroconversion.
HHV-8 serostatus was defined by results of the screening-confirmation protocol; samples that were positive for at least 1 antigen (ORF65 or ORF73) in both the HHV-8 EIA system and the corresponding confirmation assay were considered to be HHV-8 seropositive. Samples that were seronegative in the EIA system were considered HHV-8 seronegative. Samples that were positive in the HHV-8 EIA system but negative in the corresponding confirmation assay were considered to be false positive and were recorded as HHV-8 seronegative in further analyses. In all, 56 (62.9%) of 89 EIA-reactive serum samples were recorded as HHV-8 seronegative. Intake characteristics of participants with false-positive (n ¼ 56) or seronegative (n ¼ 1093) test results were compared by using x 2 tests of independence and Mann-Whitney U tests, but no differences in characteristics were found.
HIV-1 antibodies were detected using 1 of 2 commercial assays (Abbott Laboratories or Vironostika, Organon Teknika), and positive results were confirmed by Western blot analyses. Hepatitis C virus (HCV) antibodies were detected by a third-generation EIA (EIA 3.0; Abbott Laboratories) and were confirmed by the thirdgeneration strip immunoblot assay (RIBA; Chiron). Hepatitis B virus (HBV) antibodies were detected by using the Hepanostika anti-HBc Microelisa System (Organon Teknika). HBV and HCV data were available for 447 and 351 participants, respectively [11] . The proportion of injection drug users was higher among participants who were tested for HBV (91.0%) or for HCV (77.9%) than among those who were not tested for HBV (83.0%) or for HCV (72.9%).
Statistical analyses. All analyses were performed separately for men and women, since they comprised markedly different groups. Seroprevalence of HHV-8 was calculated at study entry, and risk factors for seropositivity were investigated by logistic regression analyses. Next to a combined variable of IDU and shared injection equipment, all univariately significant variables were included in the multivariate model by using a stepwise forward procedure. Risk factor analyses were repeated by using backward procedures or exclusion of subjects in the seronegative group who initially had falsepositive assay results, but risk estimates were similar to those described in Results (data not shown). No additional risk factors were found when men and women were analyzed as a combined group.
Results
General characteristics at enrollment. The study population comprised 1179 drug users, of whom 503 (42.7%) were women. The median age was 30 years (interquartile range [IQR], 26-34 years). Of the participants, 93.0% were of northern or central European nationality. Most (79.8%) had a history of IDU (median use, 9 years; IQR, 5-14 years) and used mainly heroin and/or cocaine. Seventy percent of injection drug users reported needle sharing. Most women participants (84.1%) had worked as prostitutes (median duration, 6 years; IQR, 2-11 years), and 33.8% reported consistent use of condoms with clients.
Prevalence and incidence of HHV-8 infection. Of 1179 drug users, 33 were HHV-8 seropositive at their most recent cohort visit, of whom 30 (2.5%) were also seropositive at study entry. Twenty-three (3.4%) of 676 were men and 7 (1.4%) of 503 were women (odds ratio [OR] for men, 2.50; 95% CI, 1.06-5.86; P ¼ :04). Two men and 1 woman seroconverted for HHV-8 during follow-up, resulting in an incidence rate of 0.08 (95% CI, 0.02-0.30), 0.05 (95% CI, 0.01-0.37), and 0.07 (95% CI, 0.02-0.20) seroconversions per 100 person-years for men, women, and the total group, respectively.
Risk factors for HHV-8 seropositivity at study enrollment. Among women drug users, associations of borderline significance were observed between HHV-8 seropositivity and history of sexual contact with bisexual men and lack of a steady partner (table  1) . Seropositivity was not associated with a history of prostitution; however, female prostitutes who never used condoms with their clients had a higher risk of being seropositive. Furthermore, IDU was not significantly associated with seropositivity. A multivariate model was not constructed because of the small number of HHV-8-seropositive women.
Among men drug users, univariate and multivariate risk factors for HHV-8 seropositivity were history of homosexual contact and Mediterranean nationality (table 1). Seropositivity was not associated with IDU, duration or frequency of injection, or type of drug used. When we regrouped the men into high-and lowrisk groups for HHV-8, presence or absence of homosexual contact, and/or Mediterranean nationality, the lack of association between injection practices and HHV-8 seropositivity remained in both high-and low-risk groups (data not shown).
Association between HHV-8 infection and HIV-1, HBV, and HCV infection. HIV-1 antibodies were detected in 277 (23.6%) of 1173 participants, HBV antibodies in 255 (57.0%) of a subgroup of 447 participants, and HCV antibodies in 326 (92.9%) of 351 participants. Infections with HIV-1, HBV, and HCV, but not HHV-8, were strongly related to IDU (table 2). In addition, HHV-8 was not related to any of the other viruses, whereas HIV-1, HBV, and HCV were strongly related to each other (between HIV-1 and HBV, OR, 3.66; 95% CI, 2.19-6.14; between HIV-1 and HCV, OR, 8.66; 95% CI, 2.01-37.32; and between HBV and HCV, OR, 14.17; 95% CI, 3.92-51.23). None of these parenterally transmitted infections was associated (using a combined variable on HIV-1, HBV, and HCV) with HHV-8 seropositivity (OR, 1.59; 95% CI, 0.45-5.64).
Discussion
We investigated HHV-8 infection in a large cohort of drug users (injection and noninjection) who were at risk for HIV-1 infection. Prevalence and incidence were low in this group. Homosexual contact and Mediterranean nationality were associated with HHV-8 seropositivity among men and commercial unprotected sex, lack of a steady partner, and sexual contact with bisexual men among women. Of importance, HHV-8 sero-positivity was not associated with injection behavior or with infection with HIV-1, HBV, or HCV, whereas these 3 viruses were related to each other and to IDU.
The strength of this study lies in the length of follow-up (average, 4 years per person), serial collection of serum samples and behavioral data (mean, 9 measurements per person), and use of a screening-confirmation protocol to detect the presence of HHV-8 antibodies. Because HHV-8 assays still lack optimal specificity, it is important that a confirmation step be incorporated in low-prevalence settings (e.g., among drug users) to avoid large numbers of false-positive results.
Seroprevalence rates range from 3.2% to 49.1% in other studies of drug users in Europe and North America [8, 9, [12] [13] [14] . Variations in seroprevalence may well reflect real (geographic) differences. However, part of the variation is likely due to dissimilar serologic methodologies, since comparatively high HHV-8 seroprevalence rates conflict with the low proportion of KS in HIV-1-infected drug users. In 2 previous studies, half of the HIV-1-and HHV-8-coinfected homosexual men developed KS within 10 years [5, 7] ; however, in our cohort of drug users, only 1 case of KS was diagnosed in more than a decade of follow-up, which is in complete agreement with the low HHV-8 seroprevalence and seroincidence. Because of the low number of seroconversions, we were constrained to examine risk factors at study enrollment. Cross-sectional risk factor analyses to determine a mode of transmission should be interpreted with caution, since the moment of infection is unknown and behavior may change over time [6] . Sexual contact with homosexual or bisexual men and unprotected sex (for women) are risk factors that are consistent with sexual transmission of HHV-8 and are well supported by numerous studies of homosexual men and some studies of heterosexuals [6] [7] [8] [9] . The association between seropositivity and the lack of a steady partner may reflect sexual transmission, because women without steady partners more often reported commercial unprotected sex and sex with bisexual men (data not shown). Mediterranean nationality as a risk factor for HHV-8 agrees with our finding among homosexual men and with the high seroprevalence of HHV-8 in southern Europe and the Mediterranean basin [2, 6] .
The low seroprevalence and seroincidence in our study are unlikely to be consequences of lack of exposure to HHV-8; 22.7% of participants reported sexual contact with homosexual or bisexual men, a group with high HHV-8 seroprevalence rates [2] . Most participants injected drugs and shared needles, and the presence of HIV-1, HBV, and HCV infection in this cohort demonstrates the occurrence of blood-to-blood contact. Therefore, if needle sharing and blood-to-blood contact held major risks for the transmission of HHV-8, the observed prevalence and incidence of infection should be higher. In addition, Greenblatt et al. [9] found that sexual activity and drug use were more important predictors for HHV-8 seropositivity than drug injection per se and speculated that the mode of HHV-8 transmission is a drug-associated behavior. Similarly, in our cohort of homosexual men, univariate associations with drug use were explained by sexual practices in multivariate analyses [6] .
Although our risk factor analyses do not support frequent or regular transmission of HHV-8 by IDU, we must take into account that we deal with low power (few HHV-8-infected subjects) to detect an association, and we cannot exclude parenteral transmission of HHV-8. Transmission of HHV-8 through needle sharing has been suggested previously [8] . Nonetheless, infrequent transmission through blood products is supported by a study of persons who received blood products from HIV-1-and HHV-8-coinfected donors; 10 of 14 recipients seroconverted for HIV-1, whereas none seroconverted for HHV-8 [15] .
In conclusion, HHV-8 seroprevalence and seroincidence are low in our cohort of drug users and mirror the low proportion of KS in HIV-1-infected drug users. Risk factors for seropositivity reflect well-known risk groups for HHV-8 infection and are consistent with sexual transmission of HHV-8. Needle sharing was not found to be a risk factor for transmission among drug users in our cohort. In contrast to HIV-1, HBV, or HCV, transmission of HHV-8 through IDU is rare among drug users in Amsterdam.
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